Dr Edward Loftus reviews details of the pivotal trial where upadacitinib emerged a superior alternative to placebo for induction and maintenance therapy among patients with moderate-to-severe Crohn’s disease.

In this podcast, Dr Adam Faye explains the association between various patient-level demographic, nutritional and clinical factors and risk for complications among older patients who underwent intestinal resection for inflammatory bowel disease.

--

Adam Faye, MD, is an assistant professor of medicine and population health at the Inflammatory Bowel Disease Center at NYU Langone Health.

--

Dr Gil Melmed from Cedars-Sinai talks with Drs Raymond Cross and Millie Long about the importance of vaccines, cancer screenings, and other aspects of overall health maintenance for patients with inflammatory bowel disease.

IBD Drive Time: Christina Ha, MD, on Biosimilars by Gastroenterology Learning Network

Guest Christina Ha, MD, from the Mayo Clinic in Arizona, reviews key points about the advent of biosimilars, including reassuring patients and countering the "nocebo" effect, with hosts Drs Raymond Cross and Millie Long.

The 2 leading gastrointestinal societies in United States—the American Gastroenterological Association and the American College of Gastroenterology—collaborated to produce guidance on pharmacological agents available for the treatment of chronic idiopathic constipation.

In part 2 of their podcast on Helicobacter pylori, Drs William Chey and Brian Lacy talk about the risks of untreated disease and the various types of treatment available.

In this first of a two-part podcast on Helicobacter pylori, Drs Brian Lacy and William Chey discuss the prevalence of H pylori infection and how to best diagnose the condition.

Dr David Rubin from the University of Chicago discusses the hurdles of prior authorization and ways to manage the process to ensure patients can receive their IBD therapies, with guests David Choi, PharmD, and Mona Shah, MPH.

Dr Gideon Hirschfield from the University of Toronto Centre for Liver Disease discusses the potential of new drugs, including selective PPAR agents such as seladelpar, for the treatment of primary biliary cholangitis.